Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 8
Submit an article Journal homepage
1,006
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse

Neta GoldschmidtHematology Department, Hadassah-Hebrew University Medical School, Jerusalem, Israel; Correspondence[email protected]
,
Netanel A. HorowitzDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;
,
Vered HeffesDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;
,
Fares DarawshyHematology Department, Hadassah-Hebrew University Medical School, Jerusalem, Israel;
,
Tatiana MashiachQuality Assurance Unit, Rambam Health Care Campus, Haifa, Israel;
,
Adir ShaulovHematology Department, Hadassah-Hebrew University Medical School, Jerusalem, Israel;
,
Moshe E. GattHematology Department, Hadassah-Hebrew University Medical School, Jerusalem, Israel;
&
Eldad J. DannDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; ;Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa, Israel; ;Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
 show all
Pages 1890-1898 | Received 07 Aug 2018, Accepted 26 Dec 2018, Published online: 28 Jan 2019

References

  • Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;2016:
  • Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045.
  • A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994.
  • Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861.
  • Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–842.
  • Gang AO, Strom C, Pedersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 2012;23:147–153.
  • Wasterlid T, Hartman L, Szekely E, et al. Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol. 2015
  • Melen CM, Enblad G, Sonnevi K, et al. Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Br J Haematol. 2016;175:614–622.
  • Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858–1867.
  • Wilson WH, sin-Ho J, Pitcher BN, et al. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/alliance 50303. Blood. 2016;128:469a.
  • Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250–1259.
  • Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 - the Southwest Oncology Group. J Clin Oncol. 2009;27:114–119.
  • Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23:1267–1273.
  • Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13:1099–1107.
  • Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. JCO. 2016;34:3150–3156.
  • Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110:29–36.
  • Adams HJ, Kwee TC, Fijnheer R, et al. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol. 2014;89:726–731.
  • Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283–4290.
  • Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168:654–662.
  • Holte H, Leppa S, Bjorkholm M, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24:1385–1392.
  • Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–4289.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.